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Abstract
Background: It is unclear if the use of hormone therapy (HT) in carriers of BRCA mutations improves the quality
of life (QOL) without increasing the risk of breast cancer following a risk-reducing salpingo-oophorectomy (RRSO).
Our objective was to assess the effect of HT on QOL and breast cancer risk, after RRSO.
Methods: We searched MEDLINE, EMBASE, CINHAL, and others, from inception to July 22, 2016, to identify relevant
studies. Two reviewers independently screened identified records for controlled trials and observational studies that
addressed the effect of HT on QOL and breast cancer risk in women with BRCA mutations, post RRSO. Two
reviewers independently extracted data on populations, interventions, comparators, outcomes, and methodological
quality. Studies addressing the same outcome were synthesized using written evidence summaries or tables.
Results: Of the 1,059 records identified, 13 met our inclusion criteria. All studies were observational. Six studies
assessed the effect on QOL. Of these, 3 showed improvement in QOL with HT use. The risk of breast cancer was
evaluated in 4 studies. The mean duration of follow-up was 2.6 years (range 0.1-19.1). The risk of breast cancer did
not change with HT use in all 4 studies.
Conclusions: Cumulative evidence from our review suggests that short-term HT use following RRSO improves QOL.
The effect on breast cancer risk is still unclear. There are too few long-term studies to draw any strong conclusions.
The need for future well-designed RCTs for more established evidence is imperative.
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Background
BRCA mutations are associated with an increased risk of
breast and ovarian cancer. In women with mutations of
BRCA1 genes, the average cumulative risk for breast
cancer by age 80 years is 67% and for ovarian cancer
45% [1–4]. In BRCA2 carriers, the average cumulative
risks are 66% and 12%, respectively [1–4]. Risk-reducing
saplingo-oophorectomy (RRSO) offers reduction in the
risk of ovarian cancer of approximately 80%, among
BRCA1 and 2 carriers, and of 50% for breast cancer [5].
However, more recent evidence suggests that breast
cancer-risk reduction with RRSO may not be significant,
particularly for BRCA1 carriers [6, 7]. Since cancer risk
estimates for BRCA carriers are age-dependent and tend
to be higher in younger age populations, [7] current
guidelines recommend RRSO for BRCA carriers before
age 40 years or after completion of child-bearing [8–11].
An immediate consequence of RRSO in premenopausal
women is surgical menopause. Surgical menopause is
associated with symptoms that can significantly affect a
woman's quality of life (QOL), including vasomotor and
urogenital symptoms, sexual dysfunction, sleep distur-
bances, and mood changes [12]. Furthermore, these
women are at risk of long-term sequelae such as osteopor-
osis, cardiovascular diseases, and cognitive impairment
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[13–15]. In women with early menopause, who have no
contraindications to hormone therapy (HT), current
guidelines recommend the use of HT until the average
age of menopause [16–18]. As BRCA mutation carriers
would ideally undertake RRSO at an earlier age than
women who perform it for other benign reasons or who
go through early natural menopause, guidelines specific to
BRCA mutation carriers suggest the consideration of
short-term HT use due to the unknown nature of long-
term safety [10].
The concern in women with BRCA mutations is that
HT may further increase breast cancer risk following a
RRSO. The Women's Health Initiative (WHI) randomized
trials found an increased risk of breast cancer with estro-
gen plus progestin, although not with estrogen alone [19].
Data from short-term observational studies assessing the
risk of breast cancer with HT use after RRSO are incon-
sistent, and at this time it is unclear if HT increases breast
cancer risk following a RRSO [20, 21].
Carriers of BRCA mutations and women at high risk
for breast cancer are often challenged by the decision to
undertake RRSO due to the health consequences associ-
ated with surgical menopause, and the need for HT that
may further increase their breast cancer risk. In 2014,
Marchetti et al addressed this important topic in a
narrative review, but the lack of details of the literature
review method lead to concern about the rigor and
completeness of the review [22]. Similarly, in early 2016,
Birrer et al published a review of evidence about the
safety of HT in women with BRCA mutations [23]. Even
though they reported in their title and methods that they
conducted a systematic review, the study lacked the
main elements of a systematic review, such as a compre-
hensive literature search, an assessment of the methodo-
logical quality of studies included, and transparency in
reporting the methods and findings [23].
We, therefore, performed a systematic review to assess
the effect of HT on QOL and breast cancer risk in
women who have BRCA mutations and who also under-
went RRSO for breast and ovarian cancer-risk reduction.
The effect of HT on other short and long-term out-
comes was also evaluated.
Methods
Our study was designed and conducted in accordance
with the guidelines for Meta-Analyses and Systematic
Reviews of Observational Studies (MOOSE) [24].
Eligibility criteria
Eligible studies included women who had BRCA1/2
mutations or who had a high risk of breast and ovarian
cancer (as defined by the original study authors) but had
not undergone genetic testing, and who had undergone
RRSO for cancer-risk reduction. Studies comparing the
effect of HT (with no restriction on type, dose, regimen,
or route of administration) to placebo, non-exposed
group or baseline, qualified for inclusion. All controlled
trials and observational studies (including prospective
and retrospective cohort studies, case-control studies,
and cross-sectional studies) were included. Review
papers were screened for cited articles. Exclusion criteria
included qualitative studies, hypothetical decision ana-
lysis, editorials and studies that did not assess the effect
of HT on outcomes of interest. Studies that included
women with a personal history of breast cancer were
not explicitly excluded.
Outcome measures
Primary outcomes were QOL (general and menopause-
specific) and breast cancer risk. Secondary outcomes
included: vasomotor symptoms, vulvovaginal atrophy
(VVA), sexual function, mood, sleep disturbance, bone
loss, cardiovascular disease, stroke, venous thrombo-
embolism, and mortality.
Data sources and search strategy
A systematic literature search was conducted by a librarian
(SC) to identify all relevant published and unpublished stud-
ies. Searches using both controlled vocabulary and natural
language were performed in databases including MEDLINE
(1946 to March 7, 2016), EMBASE (1974 to March 7, 2016),
and CINHAL (inception to March 7, 2016) (Additional file 1).
Natural language search terms were derived from three main
concepts: 1) RRSO, 2) BRCA mutations or high risk of breast
and ovarian cancer, and 3) HT. Grey literature searches were
conducted in SCOPUS, Web of Science, Google Scholar, Pro-
quest, Dissertations and Theses and clinical trials registries,
from inception to July 22, 2016 (Additional file 2). Other
searches included hand searches of the reference list of review
papers; and citation search of studies included in the system-
atic review. To increase the sensitivity of our search no
language or date restrictions of publications were applied.
Study selection
Two-step screening for eligibility was performed independ-
ently by 2 reviewers (TS and NY), with disagreements re-
solved by consensus. First, titles and abstracts were screened
to select articles eligible for further review. Second, full-text
of relevant articles was reviewed for eligibility. Reviewer
agreement for confirmation of eligibility was 100%.
Data extraction and quality assessment
Data extraction was completed independently by two
reviewers (TS, AB), and discrepancies resolved by a third
reviewer (NY). Data elements extracted included: manu-
script characteristics; study design and settings; population
characteristics; interventions; comparators; outcomes; and
adjustments for potential confounders. The risk of bias
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assessment was conducted independently by two reviewers
(TS, NY) and discrepancies resolved by consensus. The
quality of studies was evaluated using the Jadad scale for
RCTs, [25] and relevant versions of the Newcastle-Ottawa
scale (NOS) for observational studies [26]. Cut off scores
of ≥ 4 for Jadad scale and ≥7 for NOS were used to distin-
guish study quality [27]. Quality assessment scores were
used to inform sensitivity analyses to evaluate its effect on
pooled measure(s) of effect. Corresponding authors were
contacted when data on outcomes were not available.
Data synthesis
Outcome data were synthesized by tabulating together all
studies reported on specific outcomes. For each study, the
outcomes reported were grouped by HT users versus non-
users, with mean differences or measures of association as
relevant. Descriptive analysis was used for each outcome.
When sufficient homogeneity was demonstrated, out-
come data were pooled quantitatively via a meta-analysis
(as only two or three papers could be pooled for each out-
come variable the details of the meta-analysis can be found
in Additional file 3).
Results
Our search identified 1,059 records of which 51 full-text
articles were retrieved and assessed for eligibility, and 13
were included (Fig. 1.) The most common reasons for
exclusion are listed in Fig. 1. Additional file 4 lists all 51
studies reviewed for eligibility and the reason for exclusion
whenever this may apply.
Study characteristics
Table 1 lists the main characteristics of the studies and
their methodological quality. No RCTs were identified.
The mean age of women across studies was 49.87 years
(range 33-83), however, 6 studies did not report the
participants’ age [21, 28–32]. The mean age at RRSO
surgery was 45.54 years (range 24-80). Studies included
both BRCA1 and 2 carriers, except for 2, which included
only BRCA1 carriers [21, 31]. In addition to BRCA
mutation carriers, 6 studies included women who had
high risk of breast and ovarian cancer with no confirmed
genetic diagnosis [29, 32–36]. Other variables, such as
time since RRSO, body mass index (BMI), smoking
status, history of breast cancer and hysterectomy were
reported in some but not all studies. No studies included
women with personal history of breast cancer. Intervention
characteristics are listed in Table 2.
Synthesis of results
The outcomes reported for individual studies are shown
in Table 3.
Quality of life
Six studies assessed the effect of HT on menopause-specific
QOL [29, 32–34, 37, 38]. Tools of QOL assessment
varied and included Functional Assessment of Cancer
Therapy-Endocrine Score (FACT-ES) [33, 34]; Meno-
pause Symptoms List (MSL) [37], Menopause-Specific
Quality of Life-Intervention tool (MENQOL-I), [32, 38]
and Menopause Rating Scale (MRS) [29]. Where reported,
the mean age of women was 46 years or older in these
studies [33, 34, 37, 38]. Studies differed with respect to the
menopausal status at the time of RRSO surgery: 4
included pre and postmenopausal women, [29, 32, 37, 38]
2 included only pre-menopausal women [33, 34]. In one
study including both pre and postmenopausal women,
QOL was analyzed in the pre-menopausal group only
[38]. Of the 6 studies evaluating QOL, 3 studies showed
improvement in QOL, [32, 34, 38] and 3 showed no
change [29, 33, 37]. One study evaluated the effect of HT
on general QOL using the Short-form Health Survey
(SF-36) [32]. The use of systemic HT improved only
the pain domain of the SF-36 survey but none of the
other domains.
Breast cancer
Four studies looked at breast cancer risk with HT use
[20, 21, 28, 31]. One study was an update of a previous
analysis done by Eisen et al [21, 31]. All 4 studies
included women, with confirmed BRCA mutations, of
comparable mean age at the time of RRSO surgery and
with no personal history of breast cancer. Two studies
included BRCA1 and 2 mutations, with BRCA1 carriers,
Fig. 1 Flow chart for study identification and selection
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represented ≥60% in both [20, 28]. The remaining 2
studies included only BRCA1 carriers [21, 31]. All stud-
ies included ET and EPT users. The mean duration of
HT use was 3.83 years (range 0.05-25). The mean dur-
ation of follow-up for the only prospective study was 2.6
years (range 0.1-19.1) [20]. Breast cancer risk did not
change with HT use in any of the 4 studies.
Only 2 studies reported the effect of HT regimen on
breast cancer risk [20, 28]. In Gabriel et al, 3 women on
ET developed breast cancer (OR 0.48; 95% CI, 0.1-2.1),
with no cases in women on EPT [28]. Rebbeck et al.
reported that compared to ET users the risk of breast
cancer with EPT was higher but not significant (HR
2.56; 95% CI, 0.08-78.13) [20]. The effect of HT duration
of use on breast cancer was reported in one study [31].
Compared to never use, breast cancer risk did not
change with greater than 3 years of HT use post RRSO.
Other outcomes
Vasomotor symptoms
Vasomotor symptoms were assessed in 4 studies
[32–34, 38]. HT reduced the prevalence and/or severity of
hot flashes in all studies.
Sexual function
Sexual function was measured in 5 studies as part of the
QOL instruments (MENQOL, and FACT-ES), or using
the Sexual Activity Questionnaire (SAQ), Female Sexual
Function index (FSFI) or Female Sexual Distress Scale –
revised (FSDS) [29, 32, 34, 36, 38]. Two studies showed
an improvement in sexual function with HT, using the
sexual domain of MENQOL (Table 3) [32, 38]. The only
aspect of sexual activity that consistently improved with
HT use across studies was discomfort/pain [32, 36, 38].
Other aspects of sexual activity, such as pleasure, habit,
satisfaction and libido showed no improvement.
Vulvovaginal Atrophy (VVA)
Four studies measured the effect on VVA [32–34, 38]. In
2 studies, vaginal dryness was included as a component
of sexual function: taking HT improved vaginal dryness
and lubrication difficulty with intercourse [32, 38]. Two
studies measured the effect of taking HT on VVA, separ-
ate from sexual function, and did not find improvement
[33, 34].
Prevention of bone loss
Three studies evaluated the effect of HT on bone loss
[30, 33, 37]. Two studies included the time frame of
DXA screening post-RRSO (6.3 years [33] and 1.25 years
[30]). HT users had less bone loss compared to non-
users in 2 studies [33, 37].
Discussion
In our rigorously conducted systematic review, women
with BRCA mutations who had RRSO had improve-
ments in overall menopause-specific QOL with the use
of HT, as well as reduction in vasomotor symptoms and
VVA. The association of HT with breast cancer risk is
still unclear due to the lack of long-term quality studies.
QOL after RRSO is an important consideration for
women who elect to have RRSO. QOL in this population
is comparable with the general population, [39, 40]
though menopause-specific QOL may be compromised
[34, 40–43]. Several studies show that HT improves
menopause-specific QOL in symptomatic women who
Table 2 Intervention characteristics
First author Type of HT Dose of HT Route of HT Duration of HTa-mean
(range/SD)b
Challberg [33] ET, EPT and tibolone NS NS 3.4 (0.1-19)
Chapman [37] NS NS NS 6 (0.75-9)
Eisen [21] ET and EPT NS NS 3.85c (NS)
Finch [38] ET and EPT NS NS NS
Gabriel [28] ET and EPT NS NS 2.79 ± 3.22
Garcia [30] NS NS Systemic HT (60%) NS
Heiniger [29] NS NS NS NS
Johansen [36] ET, EPT and tibolone NS Systemic HT (39.28%) & local/vaginal HT (6.54%) NS
Kotsopoulos [31] ET and EPT NS NS 4.35(0.05-25)c
Madalinska [34] EPT and tibolone NS (standard) Systemic HT (Oral/transdermal) 3 ± 2.3
Michelsen [35] NS NS Systemic (Oral/transdermal) NS
Rebbeck [20] ET and EPT NS NS NS
Tucker [32] ET NS Systemic HT (20% - oral and transdermal) & local/vaginal HT (8%) NS
HT hormone therapy, ET estrogen therapy, EPT estrogen-progestogen therapy, NS not specified
ain years; bbased on the measure of variance reported in the primary study; caverage duration of use among cases and controls
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have gone through natural or surgical menopause
[44–46]. Our cumulative results are consistent with
these findings, as HT improved menopause-specific
QOL following RRSO. Although 3 of the studies that
assessed QOL showed no change with HT use, find-
ings from these studies were more prone to bias due
to confounding than studies that showed improve-
ment in QOL [29, 33, 37].
The risk of breast cancer is the greatest concern
women in the general population have when consider-
ing HT [47, 48]. This fear stems from the results of
the WHI, which showed an increased risk of breast cancer
in women on EPT for 5 or more years [19, 49]. These
results are often extrapolated to younger surgically meno-
pausal women, even though the WHI participants mean
age was 63 years at the time of study recruitment. In con-
trast, the use of ET alone in the WHI in younger women
who have had a hysterectomy showed no increase in
breast cancer risk [19, 50, 51]. Unfortunately we were un-
able to further explore the relative impact of ET versus
EPT on breast cancer or other outcomes, as few studies
reported the outcomes by specific treatment [20, 21] and
not all specified the type of HT [29, 30, 35, 37].
Several recently published narrative reviews evaluated
whether HT counteracts the breast cancer risk-reducing
effects of RRSO [12, 22, 23, 52]. However, with newer
evidence suggesting the lack of breast cancer risk-
reducing benefits from RRSO, the clinical inquiry that
rather needs to be addressed is whether HT further in-
creases the risk of breast cancer following a RRSO.
These review papers concluded that HT seems to be safe
in the short-term. We argue that given the scarcity and
methodological limitations of the available evidence, no
firm conclusions can be drawn, in the short or long
term. None of the reviews critically appraised the in-
cluded studies to assess their risk of bias. In our system-
atic review, we identified several limitations in the
studies assessing breast cancer risk. All studies were af-
fected by recall bias as HT was self-reported. Three of
the studies were not designed to capture breast cancer
incidence [21, 28, 31]. The only prospective study that
captured this outcome had a relatively short follow-up
(mean 2.6 years) [20], as well there was selection bias
due to lost to follow-up [20]. Furthermore, in this study,
breast cancer events within each group were relatively
small which may have limited the estimate’s precision
and validity. Of note, all studies we identified were in
women who had no personal history of breast cancer;
we cannot comment on whether the results of our study
could be applied to such women.
Among the other outcomes we studied, our systematic
review found that HT was associated with a reduction in
vasomotor symptoms. The benefits of HT on vasomotor
symptoms is already well established [53]. VVA was also
shown to improve with systemic HT in the pooled find-
ings from the two relevant studies in our meta-analysis
(Additional file 3). This aligns with established evidence
in the literature [54]. However, in the individual studies,
there was no significant improvement in VVA with HT.
Unfortunately information on vaginal estrogen use was
not provided in these studies. The one study that re-
ported and evaluated the effect of vaginal estrogen use
on vaginal dryness showed a reduction in the severity of
the symptom and its risk [32]. Sexual discomfort im-
proved for women taking systemic or local HT, while
other sexual dimensions were not found to be signifi-
cantly different between groups [32, 36, 38]. Sexual func-
tion is more complex than hormone levels alone, and
other factors such as emotional satisfaction, psycho-
logical status, physical health and relationship status also
need to be considered [55]. Androgen levels are reduced
in surgical menopause [56], and may contribute to low
libido [57, 58]. However, in the studies that looked at
sexual function in our review, only one study analyzed
the effect of androgen levels on sexual desire and arousal
and found no association [32]. The effect of testosterone
on sexual function was outside the scope of this review.
There are several limitations associated with our study,
mainly related to the limitations of the included studies. First,
all of the studies included in this review were observational
with a small sample size. Evidence from these studies cannot
be considered as robust as those from RCTs. Second, very
few studies provided sufficient outcome data suitable for
meta-analysis limiting the value of these analyses (Additional
file 3). Third, several studies in this review did not control
for the effect of baseline QOL score and menopause status
at the time of RRSO which are considered confounders. The
only study that controlled for baseline score showed a signifi-
cant improvement in QOL with HT [38]. Fourth, we could
not assess the effect of HT regimens (ET vs. EPT) on
different outcomes as these were poorly reported in most
studies. Conclusions from our systematic review may also be
affected by publication bias. The preferential publication of
studies, with statistically significant treatment effects, may
overestimate the effect of HT. Our search strategy aimed to
locate both published and unpublished work. We were
unable to locate any unpublished efforts.
Despite the limitations, our systematic review possesses
several strengths that differentiate it from previous less-
structured reviews on this topic [12, 22, 23]. Our review
was executed in compliance with MOOSE guidelines
(Additional file 5) and based on a pre-specified protocol
(PROSPERO registration number: 42014012997). We be-
lieve that the rigorous protocol and clear description of
our method allow clinicians and RRSO patients to be
confident that our findings are as rigorous as they can be
based on the relative paucity of good evidence to answer
the important questions that RRSO patients are asking.
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Conclusion
Cumulative evidence from our review highlights the bene-
fits of HT in improving QOL and managing common
menopausal symptoms induced by RRSO. However, no
conclusions can be drawn about the safety of HT, as far as
breast cancer risk is concerned. There are too few well-
designed long-term studies to draw firm conclusions to
guide women and their clinicians in their decision-making
about HT. Future well-designed RCTs are needed. In the
absence of clear evidence to inform the use of HT post
RRSO, clinicians and patients must carefully discuss the
potential benefits of HT as well as non-hormonal therap-
ies in improving QOL, in the context of the unknown risk
of breast cancer in this population. However, this may not
be of concern for women who opt for risk-reducing bilat-
eral mastectomy since the risk of breast cancer in this
population is negligible.
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